ZOMDFOTCPharmaceutical PreparationsFiscal year ends December 31
Zomedica Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.08−0.00 (-0.55%)
Close on Oct 19, 2026
- Market cap
- $77.40M
- P/E (TTM)
- –
- Dividend yield
- –
Zomedica Corp. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapeutic Devices | $6.75M | $5.82M | $7.40M | $6.67M | $6.18M | $5.94M | $7.13M | $6.49M | $5.71M | $5.52M | $6.98M | $5.98M | 71.0% | +9.2% |
| Diagnostics | $1.39M | $966.00K | $699.00K | $762.00K | $781.00K | $559.00K | $763.00K | $507.00K | $419.00K | $744.00K | $361.00K | $367.00K | 14.6% | +77.3% |
| Development Services | $1.37M | $2.01M | $2.37M | $662.00K | – | – | – | – | – | – | – | – | 14.4% | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumables | $6.65M | $5.47M | $5.51M | $5.38M | $5.29M | $4.50M | $4.58M | $4.71M | $4.36M | $4.01M | $4.05M | $4.48M | 69.9% | +25.6% |
| Capital | $1.84M | $1.97M | $3.45M | $2.20M | $1.65M | $1.96M | $3.30M | $2.24M | $1.73M | $2.22M | $3.27M | $1.85M | 19.3% | +11.3% |
| Engineering | $979.00K | $1.24M | $1.49M | $483.00K | – | – | – | – | – | – | – | – | 10.3% | – |
| Other | $45.00K | $111.00K | $21.00K | $36.00K | $19.00K | $47.00K | $16.00K | $47.00K | $40.00K | $28.00K | $20.00K | $15.00K | 0.5% | +136.8% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $7.86M | $7.38M | $9.12M | $6.73M | $5.56M | $5.05M | $6.68M | $5.82M | $4.90M | $5.16M | – | – | 82.7% | +41.4% |
| Foreign countries | $1.65M | $1.42M | $1.35M | $1.37M | $1.40M | $1.45M | $1.22M | $1.18M | $1.23M | $1.10M | – | – | 17.3% | +17.5% |
From the segment and revenue-disaggregation notes of Zomedica's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.